Chemerin Levels in Acute Coronary Syndrome: Systematic Review and Meta-Analysis

Abstract

Abstract Objective We evaluated the relevant published studies exploring the association between chemerin concentrations and acute coronary syndromes (ACSs). Methods A systematic search was performed in October 2021 using PubMed, Scopus, Embase, and Cochrane Library. We included full articles and assessed their quality using the Newcastle-Ottawa score. Results We found 6 studies in the systematic review and 5 of these were included in our meta-analysis. Mean difference (MD) of 41.69 ng/mL (95% CI, 10.07–73.30), 132.14 ng/mL (95% CI, −102.12–366.40), and 62.10 ng/mL (95% CI, 10.31–113.89) in chemerin levels was seen in ACS patients vs control subjects, ACS patients vs stable angina pectoris patients (SAP), and type 2 diabetes mellitus (T2DM) ACS patients vs nondiabetic ACS patients, respectively. Conclusion Chemerin levels were significantly elevated in patients with ACS compared to controls, as well as in T2DM–ACS patients compared to nondiabetic ACS patients. However, no significant MD in chemerin levels was observed between SAP and ACS patients.